GETI.B

206.3

-0.34%↓

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

ARJOB

34.56

-1.59%↓

GETI.B

206.3

-0.34%↓

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

ARJOB

34.56

-1.59%↓

GETI.B

206.3

-0.34%↓

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

ARJOB

34.56

-1.59%↓

GETI.B

206.3

-0.34%↓

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

ARJOB

34.56

-1.59%↓

GETI.B

206.3

-0.34%↓

VITR

137.5

+2.77%↑

AMBEA

127.3

-1.93%↓

ATT

65.7

-2.95%↓

ARJOB

34.56

-1.59%↓

Search

Camurus AB

Gesloten

727 2.11

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

707

Max

727.5

Belangrijke statistieken

By Trading Economics

Inkomsten

53M

292M

Verkoop

117M

676M

K/W

Sectorgemiddelde

58.708

35.724

EPS

4.08

Winstmarge

43.235

Werknemers

267

EBITDA

54M

315M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1B

42B

Vorige openingsprijs

724.89

Vorige sluitingsprijs

727

Camurus AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 aug 2025, 22:51 UTC

Winsten

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Rev $4.01B

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Adj EPS $1.84

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H EPS $1.82

27 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug 2025, 23:39 UTC

Winsten

Correction to Nvidia Earnings Article -- WSJ

27 aug 2025, 22:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 aug 2025, 22:59 UTC

Marktinformatie

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug 2025, 22:58 UTC

Winsten

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug 2025, 22:57 UTC

Winsten

South32 FY Free Cash Flow $192 Million

27 aug 2025, 22:56 UTC

Winsten

South32 FY Total Capital Expenditure $1.35 Billion

27 aug 2025, 22:56 UTC

Winsten

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug 2025, 22:55 UTC

Winsten

South32 Net Cash $123 Million at June 30

27 aug 2025, 22:54 UTC

Winsten

South32: Focused on Maintaining Strong Operating Momentum

27 aug 2025, 22:53 UTC

Winsten

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug 2025, 22:53 UTC

Winsten

South32 Extends Capital Management Program for 12 Months

27 aug 2025, 22:52 UTC

Winsten

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug 2025, 22:50 UTC

Winsten

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug 2025, 22:50 UTC

Winsten

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug 2025, 22:45 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug 2025, 22:43 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug 2025, 22:43 UTC

Winsten

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources Net Debt $123 Million at June 30

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Vergelijking

Prijswijziging

Camurus AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.